Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | USP5 | P45974 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20495345 | 0.82 | HTR2A (0.42) | HTR2APSMB1PSMB5HSD17B10TSHR | |
| SCHEMBL20495346 | 0.82 | HTR2A (0.42) | HTR2APSMB1PSMB5HSD17B10TSHR | |
| SCHEMBL11004879 | 0.82 | HTR2A (0.42) | HTR2APSMB1PSMB5HTR2CSMN1; SMN2 | |
| SCHEMBL28584265 | 0.82 | HTR2A (0.49) | HTR2APSMB1PSMB5HTR2CSMN1; SMN2 | |
| SCHEMBL29809202 | 0.82 | HTR2A (0.49) | HTR2APSMB1PSMB5HTR2CSMN1; SMN2 | |
| SCHEMBL312028 | 0.81 | USP5 (0.56) | HTR2APSMB1PSMB5TSHRKDM4E | |
| SCHEMBL31444926 | 0.81 | USP5 (0.56) | HTR2APSMB1PSMB5TSHRKDM4E | |
| SCHEMBL22552167 | 0.80 | HTR2A (0.43) | HTR2APSMB1PSMB5HTR2CSMN1; SMN2 | |
| SCHEMBL22796675 | 0.77 | HTR2A (0.46) | HTR2AHTR2CL3MBTL1HSD17B10TSHR | |
| SCHEMBL15723623 | 0.77 | HTR2A (0.68) | HTR2AHTR2CHSD17B10TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151833-A1 | SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS, LLC (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024145245-A2 | ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-4257587-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-11753393-B2 | Dihydroorotate dehydrogenase inhibitors | JANSSEN BIOTECH, INC. | 2023-09-12 | — | — | US | disclosed |
| US-20230059865-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230025130-A1 | METHODS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11505536-B2 | Dihydroorotate dehydrogenase inhibitors | JANSSEN BIOTECH, INC. | 2022-11-22 | — | — | US | disclosed |
| CN-112876413-B | Preparation and antiviral activity of 2- (isoquinoline-1 (2H) -ketone-4-yl) difluoro acetyl derivative | 南开大学 | 2022-10-28 | — | — | CN | disclosed |
| US-20220298137-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2022-09-22 | — | — | US | disclosed |
| US-10696720-B2 | Nucleoside triphosphate transporter and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | BANK OF AMERICA, N.A. | 2019-11-14 | — | — | US | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019014262-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS OF USE IN VIVO THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-01-17 | — | — | WO | disclosed |
| US-9714232-B2 | Substituted piperazine compounds and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-07-25 | — | — | US | disclosed |
| US-20160244429-A1 | Substituted Piperazine Compounds And Methods Of Use Thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-25 | — | — | US | disclosed |
| WO-2011055270-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244429-A1 | Substituted Piperazine Compounds And Methods Of Use Thereof | HTR5A, HTR2A, HTR2C | HTR2A 2/4885PSMB1 2811/4885PSMB5 760/4885 |
| US-11753393-B2 | Dihydroorotate dehydrogenase inhibitors | DHODH, DLD, DPYD | HTR2A 3526/4885PSMB1 4201/4885PSMB5 4237/4885 |
| US-10696720-B2 | Nucleoside triphosphate transporter and uses thereof | SLC35B2, SLC29A2, PNP | HTR2A 2402/4885PSMB1 4773/4885PSMB5 4248/4885 |
| US-11505536-B2 | Dihydroorotate dehydrogenase inhibitors | DHODH, DLD, DPYD | HTR2A 3526/4885PSMB1 4201/4885PSMB5 4237/4885 |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | HTR2A 2212/4885PSMB1 4037/4885PSMB5 4308/4885 |
| US-20230025130-A1 | METHODS FOR MODULATING SPLICING | RBM17, SNRPE, SNRPB2 | HTR2A 3291/4885PSMB1 2439/4885PSMB5 2245/4885 |
| US-20220298137-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | HTR2A 3526/4885PSMB1 4201/4885PSMB5 4237/4885 |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | HTR2A 3570/4885PSMB1 1339/4885PSMB5 670/4885 |
| US-20220403383-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | HTR2A 3545/4885PSMB1 2316/4885PSMB5 2431/4885 |
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | HRH2, CRHR2, CRHR1 | HTR2A 59/4885PSMB1 3276/4885PSMB5 2608/4885 |
| US-20230059865-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | HTR2A 3545/4885PSMB1 2316/4885PSMB5 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.